MetaTech Group Visits Expo 2025 Osaka, Showcasing Its Commitment to iPSC Technology Development
At Expo 2025 Osaka, a beating “mini heart” inside the PASONA NATUREVERSE Pavilion has become one of the exhibition’s highlights. This tiny heart muscle sheet, created from iPS cells by the research team of Professor Yoshiki Sawa, a leading authority in regenerative medicine in Japan, not only showcases the future of medical technology but also deeply impressed the special delegation sent by MetaTech Group.
The team remarked that “the future of medicine displayed at the Expo is actually already underway in Taiwan.”
During the visit, MetaTech’s special reporting team traveled to Japan to document the pavilion and its exhibits in detail. Kazuchika Furuishi, Director of MetaTech and Locus Regenerative Biotechnology, personally guided the delegation through the exhibition, allowing them to closely observe the artificial heart—only two centimeters in diameter yet capable of continuously beating.
“When I saw this heart beating, it was not only moving but also reminded me that Taiwan possesses similar capabilities,” Furuishi said.
“The clinical application of iPSC technology is not a distant dream. It already exists within our technological capabilities and is ready to enter the next stage of development.”
In recent years, iPSC (induced pluripotent stem cell) technology has advanced rapidly in international medicine. Its potential applications include treatments for heart disease, Parkinson’s disease, blindness, kidney failure, severe burns, and dental pulp regeneration, representing significant breakthroughs in regenerative medicine.
Japan has also begun promoting the “MyiPS” concept, with plans to commercialize cardiac muscle sheets and bring them into clinical use.
Meanwhile, Taiwan successfully cultivated a beating cardiac muscle sheet from just 10 ml of blood as early as 2022. In 2024, the full production process was demonstrated using blood from Taiwanese celebrity Kun Ling, making Taiwan one of the teams worldwide capable of mastering this technology.
“Seeing Taiwan’s presence on the global stage of regenerative medicine confirms that we are moving in the right direction,” said Ashley Yang, Executive Director of MetaTech.
She added that the company will actively seek international collaboration opportunities, pursue cross-border clinical trials, and identify potential Taiwanese partners to jointly advance the practical application of iPSC-based therapies.
Yang further emphasized that Taiwan already has a solid foundation in iPSC technology development. With breakthroughs in advanced technologies, supportive government policies, and established clinical validation systems, Taiwan has the opportunity to secure a meaningful position in the global regenerative medicine landscape.
“The future of medicine showcased at the Expo is something Taiwan is already participating in,” Yang said. “Our next step is to bring these technologies into real human lives.”
MetaTech believes that iPSC technology will become an important gateway for Taiwan’s biotechnology industry to gain global recognition. As a pioneer in the field, the company will continue strengthening research and development, strategic alliances, and technological innovation, helping Taiwan’s regenerative medicine industry integrate with the global market.
This on-site visit to Expo 2025 Osaka not only provided firsthand insights into international medical trends but also clearly demonstrated MetaTech’s forward-looking strategy within the global regenerative medicine industry chain.
Reference : https://www.setn.com/News.aspx?NewsID=1651966
